510(k) device
Dreem 3S
Beacon Biosignals, Inc. · Automatic Event Detection Software For Polysomnograph With Electroencephalograph (OLZ, Class II) · First FDA decision Aug 18, 2023, newest Nov 22, 2024Sleep apnea
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
510(k) pathway
Device trials
1
Naming "Dreem 3S"
MAUDE reports
0
Brand "Dreem 3S", since 2015
PubMed studies
0
Mentioning "Dreem 3S"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Dreem 3S
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- Dreem 3S510(k)
K242094 · Decided Nov 22, 2024 · 128 days after receipt
Device type: Automatic Event Detection Software For Polysomnograph With Electroencephalograph (OLZ) · Neurology & Neurosurgery
- Dreem 3S510(k)
K223539 · Decided Aug 18, 2023 · 268 days after receipt
Device type: Automatic Event Detection Software For Polysomnograph With Electroencephalograph (OLZ) · Neurology & Neurosurgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Dreem 3S", any status and sponsor, newest update first.
- Efficacy of the Dreem 3S Ambulatory Sleep Monitoring Device for the Evaluation of NarcolepsyCompleted
Beacon BiosignalsNot on our public-company list
NCT06531876 · 78 participants · Start Jul 1, 2024 · Primary completion Feb 27, 2026
Device: Dreem 3S recording · For: Narcolepsy Type 1; Hypersomnia; Sleep Disorder
Sites: Fontana, California; Redwood City, California; Rochester, New York · 4 sites in all
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Dreem 3S", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code OLZ
10 reports: 8 malfunction, 1 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Dreem 3S"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code OLZ.
- Sleep ProfilerAdvanced Brain Monitoring, Inc. · 510(k) 2016
- Somnum (Somnum)Honeynaps Co., Ltd. · 510(k) 2026
- DeepRESPNox Medical Ehf · 510(k) 2025
- EnsoSleepEnsodata, Inc. · 510(k) 2021
- Sleepware G3Respironics, Inc. · 510(k) 2020
- Sleep Analysis ModuleNeurotronics, LLC · 510(k) 2026
- Onera SleepMap (SLEEPMAP)Onera B.V. · 510(k) 2026
- Hypnos (369054-200)Cadwell Industries, Inc. · 510(k) 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.